Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease by Runeberg-Roos, Pia et al.
Neurobiology of Disease 96 (2016) 335–345
Contents lists available at ScienceDirect
Neurobiology of Disease
j ourna l homepage: www.e lsev ie r .com/ locate /ynbd iDeveloping therapeutically more efﬁcient Neurturin variants for
treatment of Parkinson's diseasePia Runeberg-Roos a,⁎, Elisa Piccinini a,1, Anna-Maija Penttinen a,1, Kert Mätlik a, Hanna Heikkinen a,
Satu Kuure a,2, Maxim M. Bespalov a,3, Johan Peränen a,4, Enrique Garea-Rodríguez b,5, Eberhard Fuchs c,
Mikko Airavaara a, Nisse Kalkkinen a, Richard Penn d,6, Mart Saarma a
a Institute of Biotechnology, University of Helsinki, PB 56 (Viikinkaari 5D), FIN-00014, Finland
b Department of Neuroanatomy, Institute for Anatomy and Cell Biology, University of Freiburg, Freiburg, Germany
c German Primate Center, Göttingen, Germany
d CNS Therapeutics Inc., 332 Minnesota Street, Ste W1750, St. Paul, MN 55101, USAAbbreviations: GDNF, Glial cell line-Derived
immunohistochemical; GAPDH, glyceraldehyde 3-phos
GDNF family receptor α1; GFRα2, GDNF family recepto
MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;
tagged NRTN variants N1-4; N1–4, untagged NRTN varia
PD, Parkinson's disease; pgsA 745 cells, CHO cells deﬁ
ATCC; P-TYR, phosphotyrosine; RET, Rearranged during T
tyrosine kinase receptor); SNpc, substantia nigra p
hydroxylase; WB, Western blotting.
⁎ Corresponding author.
E-mail address: pia.runeberg@helsinki.ﬁ (P. Runeberg-
1 Equal second authors.
2 Current address: Laboratory Animal Centre, University
3 Current address: University of Helsinki, Research Prog
and Biomedicum Stem Cell Centre.
4 Current address: University of Helsinki, Biomedicum,
5 Current address: Encepharm, Göttingen, Germany.
6 Current address: NTF Therapeutics, Inc., 4950 S. Chica
USA.
Available online on ScienceDirect (www.sciencedir
http://dx.doi.org/10.1016/j.nbd.2016.07.008
0969-9961/© 2016 Elsevier Inc. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 26 May 2016
Revised 4 July 2016
Accepted 13 July 2016
Available online 15 July 2016In Parkinson's disease midbrain dopaminergic neurons degenerate and die. Oral medications and deep brain
stimulation can relieve the initial symptoms, but the disease continues to progress. Growth factors that might
support the survival, enhance the activity, or even regenerate degenerating dopamine neurons have been tried
with mixed results in patients. As growth factors do not pass the blood-brain barrier, they have to be delivered
intracranially. Therefore their efﬁcient diffusion in brain tissue is of crucial importance. To improve the diffusion
of the growth factor neurturin (NRTN), wemodiﬁed its capacity to attach to heparan sulfates in the extracellular
matrix. We present four new, biologically fully active variants with reduced heparin binding. Two of these vari-
ants are more stable than WT NRTN in vitro and diffuse better in rat brains. We also show that one of the NRTN
variants diffuses better than its close homolog GDNF inmonkey brains. The variant with the highest stability and
widest diffusion regenerates dopamine ﬁbers and improves the conditions of rats in a 6-hydroxydopamine
model of Parkinson's disease more potently than GDNF, which previously showedmodest efﬁcacy in clinical tri-
als. The newNRTN variantsmay help solve themajor problemof inadequate distribution of NRTN in humanbrain
tissue.
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ect.com).1. Introduction
Parkinson's disease (PD) is a neurological disease in whichmidbrain
dopaminergic neurons are lost. While the symptoms initially can be
relieved by oralmedications and later by deep brain stimulation, the do-
paminergic neurons continue to degenerate in this chronic, progressive
disease (Kordower and Björklund, 2013). Based on animal models,
growth factors that support the survival or activity, or even restore the
function of dopaminergic neurons have been regarded as candidates
for a novel type of disease-modifying treatment. The Glial cell line-De-
rivedNeurotrophic Factor (GDNF) (Lin et al., 1993) showed a strong po-
tential in animal trials. However, although GDNF seemed beneﬁcial in
two open label clinical studies (Gill et al., 2003; Slevin et al., 2005), it
failed in a double-blind study (Lang et al., 2006). More recently also
neurturin (NRTN), a close homolog of GDNF (Kotzbauer et al., 1996)
showed only limited effects in gene therapy-based Phase 2a and 2b clin-
ical trials (Marks et al., 2010; Bartus and Johnson, 2016a; Bartus and
Johnson, 2016b; Ceregene, Press release 21.5.2013). The reason why
GDNF and NRTNwork better in animal models than in the clinical trials
is unclear (Bartus et al., 2013). GDNF and NRTN do not pass the blood-
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brain tissue their diffusion is hindered by their strong binding to extra-
cellular matrix and cell surface heparan sulfated proteoglycans
(Hamilton et al., 2001; Bespalov et al., 2011). Therefore promising re-
sults with these ligands in small rat brains (2 g), may not necessarily
be directly applicable to the much larger human brain (1300 g). In pri-
mates an efﬁcient intracranial diffusion of the growth factors is critically
important. Monkeys with the largest distribution of GDNF recovered
best from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) le-
sions (Gash et al., 2005). Monkey studies with identical catheters and
ﬂow rates as in the unsuccessful clinical trial, suggested that the trial
failed due to a poor and variable distribution of GDNF (Salvatore et al.,
2006). Autopsies on patients receiving NRTN gene therapy showed
that NRTN diffused b2 mm around the injection site (Bartus et al.,
2011), and that an enigmatically sparse tyrosine hydroxylase (TH) re-
sponse was achieved after the virus vector-driven NRTN delivery
(Bartus and Johnson, 2016a). It is worth to keep inmind that NRTN eas-
ily aggregates at high concentration, therefore its limited diffusion can-
not necessarily be compensated by a substantial increase of the dose.
Here we developed biologically active NRTN variants with reduced
binding to heparin and improved intracranial diffusion for treatment
of PD.
2. Materials and methods
2.1. Modeling and cloning of NRTN and its variants
The 3D structure of NRTN was modeled based on the crystal struc-
ture of GDNF (Eigenbrot and Gerber, 1997; Parkash et al., 2008) using
PyMol software (DeLano Scientiﬁc). For expression in mammalian
cells, human NRTN (OpenBiosystems, BC137399) was subcloned (ex-
cluding the endogenous signal and prosequence) with an IgG signal se-
quence followed by the sequence of mature NRTN as previously
described (Fjord-Larsen et al., 2005), except that pAAV-MCS (Strata-
gene) was used as a backbone. The variants were created by inverse
PCR mutagenesis (primer sequences in the supplement) and all inserts
were sequenced.
The V5-tag (GKPIPNPLLGLDST) was added to the N-terminus with
the residues (AR) between the signal sequence and the V5 tag and
(SG) between the V5-tag and the mature NRTN sequence. The cloning
(primer sequences in the supplement) was done as above. The V5-
tagged variants of human NRTN were named NV1-NV4. The cloning of
NRTN for up-scaled expression is described below.
2.2. Expression, puriﬁcation and characterization of NRTN
CHO cells were transiently transfected with GFP or the V5-tagged
NRTN variants NV1-NV4 using Turbofect (Thermo Scientiﬁc). Two
days later the media (DMEM, Sigma-Aldrich; 10% FBS, HyClone;
100 U/ml penicillin, Gibco; 100 μg/ml streptomycin, Gibco) were col-
lected, boiled with reducing Laemmli buffer and analyzed by Western
blotting with V5-antibodies (R960-25, Invitrogen).
NRTN production was up-scaled in CHO cells using constructs with-
out the prosequence and tag-sequences with the proprietary QMCF
Technology at Icosagen Ltd. (European Patent EP1851319). The NRTN
variants were puriﬁed from themedia by heparin afﬁnity chromatogra-
phy, GFRα2 afﬁnity chromatography and gel ﬁltration. The proteins
were stored in 150 mM NaCl, 10 mM Na-citrate pH 5.0 at−20 °C (pu-
riﬁcation protocol in the Supplemental material). The N-terminal se-
quence of the puriﬁed NRTN variants was determined by Edman
degradation using a Procise 494A HT Sequencer (Perkin Elmer/Applied
Biosystems, Foster City, CA). Themolecularmass of the proteinswas de-
termined using MALDI-TOF mass spectrometry (Ultraﬂex TOF/TOF,
Bruker Daltonics). To increase the detection sensitivity in Western
blots, untagged NRTN was analyzed under non-reducing conditions,
without boiling with antibodies to NRTN (AF477, R&D Systems).Commercial NRTN and GDNF (from E.coli) were from Peprotech Inc.
and ProSpec Ltd., respectively.
2.3. Heparin afﬁnity chromatography
For initial screening, media from transiently transfected CHO cells
were diluted with 10 mM HEPES, pH 7.2 and analyzed using heparin
columns (Supplementalmaterial). To characterize the afﬁnity of the pu-
riﬁed NRTN variants to heparin, we used a SMART System chromato-
graph (Pharmacia Biotech) equipped with a self-packed column
(2 × 20mm) with heparin Sepharose from HiTrap Heparin HP columns
(GE Healthcare). The ﬂow rate was 50 μl/min. After loading 2 μg of each
puriﬁed NRTN variant to the column, the samples were eluted with a
linear NaCl gradient (10 mM HEPES, pH 7.2, with NaCl up to 2 M). The
elution wasmonitored by A214 nm and the corresponding salt concen-
tration by measuring conductivity.
2.4. RET-phosphorylation and cell-based binding assays
Both assays were done as described in Supplemental material and
(Virtanen et al., 2005). When puriﬁed NRTN variants, commercial
NRTN or GDNF were used in RET-phosphorylation assays, they were di-
luted in DMEM. In cell-based binding assays competition of the 125I-
NRTN variants was performed with the unlabeled NRTN variants in
DMEM with 0.5% BSA and 0.2% dry milk (containing soluble heparan
sulfates). Monitoring of 125I-NRTN was done either from cell lysates
using a gamma counter (Perkin Elmer Wizard, 1480 automatic) or
from intact cells using LigandTracer Grey (Ridgeview Instruments AB).
In both cases IC50 was calculated based on 4–9 parallel data points
with GraphPad Prism. Thereafter the mean IC50 was determined based
on 2–5 independent measurements. As the concentration of 125I-NRTN
(50 pM) was much lower than the IC50 values obtained, the IC50 values
correspond approximately to Kd (dissociation constant) values.
2.5. In vitro survival assay on embryonic dopaminergic neurons
Dissociatedmidbrain cultures from E13.5 NMRImicewere prepared
(Planken et al., 2010), ﬁxed at 5DIV and stained with anti-TH antibody
(AB 1542, Millipore) and Cy3 afﬁnity pure donkey anti-sheep IgG
(713-165-147, Jackson). Quantiﬁcation of TH-positive cells was done
using images analyzed with Image-Pro Plus 5.1.2.59, with constant in-
tensity and size range criteria throughout an experiment. The number
of TH-positive cells for each data pointwas the average of at least 2 rep-
licate micro islands. For inter-experiment normalization, this average
was divided by themean of all of the data pointswithin the correspond-
ing experiment. The resulting relative number of TH-positive cells in
each experiment was used to calculate the average of all of the experi-
ments (n=3–8),ﬁnally expressed as per cent of the number of TH-pos-
itive cells surviving without added growth factors.
2.6. In vitro organ culture of kidney explants
E11.5 mouse urogenital blocks were dissected and cultured on
Transwell ﬁlters (Fisher) in a Trowell-type system (Sainio et al., 1997)
in DMEMmedium (10% FCS, 1% Glutamax and 1% penicillin/streptomy-
cin), supplemented with 500 ng/ml WT, NRTN variants N2 or N4. After
48 h, the explants were stained for calbindin D28K (sc-7691, Santa
Cruz).
2.7. Immunocytochemical staining
NRTN variants were transiently expressed (2 days) in CHO cells. The
mediawere stored at+4 °C. A second set of CHO cellswas plated on un-
coated cover-slips (2 days), transfectedwith GFRα2 (24 h) and exposed
to the stored media containing the different NRTN variants. The cells
were incubated with media for 10 min, rinsed with DMEM, ﬁxed with
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blocked in 1% BSA and stained with V5-antibodies (R960-25,
Invitrogen) and CY3-conjugated donkey anti-mouse antibodies
(715.165.151, Jackson). For the second assay, with CHO cells and CHO
cells deﬁcient in heparan sulfate (pgsA 745 from ATCC), the cells were
not permeabilized. The nuclei were stained with Hoechst (Invitrogen).
2.8. In vivo diffusion assays in rats
To characterize the diffusion of NRTN in the brain tissue of Wistar
rats, each protein (5 μg in 10 μl) was injected using stereotactic surgery
into the left striatum (AP +1.0, ML +2.8, DV−6.0, −5.5, −5.0 and
−4.4 mm) as described below. After 24 h the rats were transcardially
perfused with cold PBS and 4% PFA. The brains were removed and
post-ﬁxed in 4% PFA for 24 h. Following cryosectioning (40 μm) the
slices were processed and stained with goat anti-NRTN antibodies
(AF477, R&D Systems, 1:1000) (Voutilainen et al., 2009). For diffusion
volume measurements, every sixth section was analyzed with the
Cavalieri estimator function of the StereoInvestigator platform
(MicroBrightField) attached to an Olympus BX51microscope. The spac-
ing of the grid was 250 μm.
2.9. In vivo assays in a rat 6-hydroxydopamine (6-OHDA) lesion model
All trials withmaleWistar rats were carried out according to the lab-
oratory animal care guidelines of the National Institute of Health, and
were approved by the State Provincial Ofﬁce of Southern Finland. Desip-
ramine hydrochloride (15 mg/kg, Sigma-Aldrich) was administered in-
traperitoneally to the animals thirty minutes before 6-OHDA injection
to protect the noradrenergic nerve terminals. The rats were anesthe-
tized with isoﬂurane (Baxter), the left brain hemisphere was exposed
through craniectomy and 7 μl of 6-OHDA (4 μg/μl, Sigma-Aldrich) was
infused (0.5 μl/min), equally distributed between four sites into the stri-
atum (AP +1.0, ML +2.8, DV−6.0,−5.5, −5.0 and−4.4 mm from
scull). The needle was left in place for another 5 min before withdraw-
ing. The hole in the skull was ﬁlled with bone wax (Surgical Specialties
Corporation) and thewoundwas closed. Twoweeks after the lesion, an-
imals rotating ipsilaterally (see below) N220 times per 120minwere se-
lected for stereotactic injection of the protein solutions (5 μg in 10 μl
buffer) at a speed of 1 μl/min equally distributed between the identical
four coordinates as above. The needle was withdrawn and the wound
closed as above.
The rats were tested for amphetamine-induced rotation behavior
(Kirik et al., 2000) 8 and 12 weeks after the lesion. Motor asymmetry
was monitored in automated 25 rotometer bowls (Med Associates,
Inc.) for 120 min after injection of amphetamine sulfate (2.5 mg/kg
s.c. Sigma-Aldrich). The net rotation asymmetry score for each test
was calculated by subtracting contralateral turns from ipsilateral turns
to the lesion.
The forelimb use in spontaneous rearing was assessed using a cylin-
der test (Kirik et al., 2000) 6 and 10weeks after the lesion. The ratswere
monitored for 5 min as theymoved freely in the plexiglass cylinder (di-
ameter 20 cm). The contacts made by each forepaw with the cage wall
when rearing were scored by a blinded observer. The percentage of im-
paired forelimb contacts was calculated.
After 12 weeks the rats were transcardially perfused with saline and
4% PFA. The brains were cryosectioned (40 μm) and stained with bio-
tinylated mouse anti-TH-antibodies (MAB318, Millipore). The number
of TH-positive cells in the substantia nigra pars compacta (SNpc) and
the optical density of the TH-positive ﬁbers in the striatumwere deter-
mined as previously described (Voutilainen et al., 2009). Cell numbers
were counted using unbiased stereology and StereoInvestigator and
are expressed for each animal as themean cell numbers from 9 sections,
percentage of the intact side. The ﬁber densitywas determined and pre-
sented asmean density (9 sections/brain), percentage of the intact side.
The analyses were conducted in blinded manner by the experimenter.2.10. In vivo diffusion assays in monkeys
Two cynomolgusmonkeys (Macaca fascicularis) (from Covance Inc.)
were implanted with bilateral intraputamenal catheters (Renishaw
plc.) at Northern Biomedical Research. In total four catheters were
allowed to heal in place for approximately 4 weeks, after which
Magnevist® was administered for MRI-scanning (28-day intervals).
On study day 90, the animals were administered Magnevist®, and
then GFLs at a rate of 5 μl/min: N2 (170 μg at 1.0 μg/μl), N4 (170 μg at
0.83 μg/μl) and GDNF (225 μg at 1.0 μg/μl). The ﬁrst animal received
N4 in the left putamen and N2 in the right putamen; the second animal
received GDNF in the left putamen. The infusion was followed by MRI.
After necropsy, tissues were harvested and processed for IHC staining
of GDNF (1:500, AB-212-NA, R&D Systems) and NRTN (1:200, AF477,
R&D Systems) (Ai et al., 2003). Three marmoset monkeys (Callithrix
jacchus) were bilaterally injected at Encepharm ﬁrst with 5 μg of
GDNF at 0.5 μg/μl (1 μl/min) to one side and then with 5 μg of N4 at
0.5 μg/μl (1 μl/min) to the other side. After necropsy, tissues were har-
vested, processed and stained for GDNF and NRTN as above. The mon-
key diffusion volumes were determined with the StereoInvestigator
platform with sections 1 mm apart.
2.11. Expression analysis of NRTN receptors
The expression of GFRα1, GFRα2 and RET mRNAs in human brain
tissues was analyzed by RT-PCR. Total RNA from human brain
(Clontech) and poly(A)+ RNA from human substantia nigra, globus
pallidus and putamen (T. Timmusk, Ethical Committee at Tallinn Tech-
nical University, (Timmusk et al., 1993) were used (1 μg) as templates
for ﬁrst-strand cDNA synthesis with RevertAid H Minus Reverse Tran-
scriptase (Fermentas), using oligo(dT)18-primers. RNA was substituted
with water as a control (W1). For PCR, 10% of the synthesized cDNA
was used as a template (primer sequences in the supplement). For
each primer pair a water control substituting the cDNA (W2) was in-
cluded. All the PCR reactions were performed using Phusion Hot Start
II (Finnzymes/Thermo Scientiﬁc) with themanufacturer's 3-step proto-
col, 35 cycles. The annealing temperatures were 63 °C (GFRα1), 60 °C
(GFRα2), 65 °C (RET) and 61 °C (GAPDH).
3. Results
3.1. Modeling and modiﬁcations of human NRTN
To design NRTNvariantswith lowered afﬁnity to heparin,we started
by predicting the location of putative heparin binding sites. The consen-
sus sequences for heparin-binding are BBXB or BBBXXB (Cardin and
Weintraub, 1989), where B is a basic amino acid and X is any residue.
However, proteins lacking these consensus sequences may still bind to
heparin (Delacoux et al., 2000). The initial analysis of the primary se-
quence of NRTN (Fig. 1) revealed a stretch of residues in the heel region
(51RRLRQRRRLRRER63) which ﬁts with the potential heparin-binding
site criteria. Since heparin or heparan sulfates are linear polymers, the
positively charged residues must be aligned in space. At least three res-
idues should point in the same direction and be in close proximity to
each other. To pinpoint the potential heparin-binding sites in NRTN
which comply with this spatial rule we modeled the 3D structure of
NRTN (Fig. 1) based on the known structure of GDNF (Eigenbrot and
Gerber, 1997; Parkash et al., 2008). As the stretch of arginines
(51RRLRQRRRLRRER63) is much longer than a single consensus se-
quence, and the area of positively charged arginines at the surface of
NRTN is rather large, we substituted three amino acids (in variants N1
and N2) which were distributed over the surface of the protein. In var-
iant N3 (ﬁve point mutations) we combined the mutations of N1 and
N2, except that we restored the last arginine (RRLRQRRRLRRER)
which is conserved in NRTN, ARTN and PSPN. The other basic residues
in this region are not conserved among the GFLs. PSPN does not bind
Fig. 1.Modeling of NRTN and design of new NRTN variants. (A) Model of NRTN, based on the crystal structure of GDNF. The beginning (V45) and end (R56) of the helix (heel) are shown
with arrows. The location of mutated amino acids is shown in blue and red. (B) Overviewofmutated amino acids inNRTN variants N1-N4. For N1-3 themutated amino acids are shown in
blue and red in accordancewith (A), for N4 the sequence copied fromPSPN is highlighted in gray, the othermutated residues are shown in graywithout highlighting. (C) Primary structure
of WT NRTN. Arrows indicate the location of two experimentally determined N-termini. The sequence shown in (B) is highlighted in red.
Fig. 2. Quantiﬁcation of the puriﬁed untagged NRTN variants. Equal amounts of the
puriﬁed NRTN variants were compared to each other and to commercial NRTN from E.
coli on a 15% SDS-PAGE, stained with Coomassie brilliant blue.
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substituted for the heel region of NRTN the corresponding heel region
of PSPN (ARLQGQG), and prolonged the sequence (ALVGS) to match
the length of the original NRTN sequence (RRLRQRRRLRRE) (Fig. 1).
3.2. Initial screening for biologically active NRTN variants not binding to
heparin
NRTN is homodimeric with a characteristic cysteine knot structure
composed of seven disulﬁde bridges. Puriﬁcation of over-expressed re-
combinant proteins with disulﬁde bridges from E. coli often requires
harsh denaturation/renaturation and monomerization/dimerization
procedures (Lin et al., 1993; Horger et al., 1998). NRTN produced in
mammalian cells has a higher biological activity in vitro than NRTN
expressed in E. coli (Hoane et al., 2000), maybe due to the stringent
quality control of secreted proteins in mammalian cells. Therefore we
expressed the NRTN variants in mammalian cells. As the secretion of
NRTN frommammalian cells is impaired by the prosequence, we delet-
ed it. We also replaced the endogenous ER-signal sequence with that of
IgG and added a V5-tag to the N-terminus of themature protein (Fjord-
Larsen et al., 2005). All V5-tagged NRTN variants (NV1-NV4 and WT
NRTN) were secreted from CHO cells. GDNF and NRTN bind to GDNF
family co-receptors α1-2 (GFRα1-2) and activate the receptor tyrosine
kinase RET. NRTN has a slightly higher afﬁnity for GFRα2, while GDNF
has a higher afﬁnity for GFRα1 (Cik et al., 2000; Runeberg-Roos and
Saarma, 2007). Our initial screening showed that the unpuriﬁed NRTN
variants were active in RET-phosphorylation assays in vitro in the pres-
ence of either GFRα2 or GFRα1, and displayed decreased afﬁnities for
heparin (Fig. S1).
3.3. Proteolytic resistance of the NRTN variants
Unexpectedly, the concentration of the V5-tagged variants NV2 and
especially NV4 was higher in the media of transiently transfected CHO
cells than that of WT NRTN, NV1 and NV3 (Fig. S2). Similar results
were obtained with ARPE-19 cells and with untagged NRTN variants
from stably transfected CHO suspension cells. We found that the in-
creased concentrations of NV2 and NV4 are not explainable by differen-
tial protein secretion or adhesion. As WT NRTN and NV2 are more
sensitive to proteolytic degradation than NV4, an improved resistanceto proteolytic degradation may at least partly explain the result
(Fig. S2).3.4. Puriﬁcation and characterization of the NRTN variants
The expression of all NRTN variants was up-scaled in CHO suspen-
sion culture cells. Neither the prosequence nor the V5-tag was included
in the ﬁnal expression constructs. The untagged variants are called N1-
N4. Normally gel ﬁltration, cation exchange and heparin columns are
used for the puriﬁcation of GFLs (Lin et al., 1993; Horger et al., 1998).
Since the NRTN variants have very different heparin afﬁnities and pI
values (WT: pI 9.01, N1: pI 8.27, N2: pI 8.27, N3: pI 7.01, N4: pI 6.33),
we puriﬁed all NRTN variants based on their afﬁnity to GFRα2. The ap-
proximate yields per ml of media were: 0.4 μgWT, 0.6 μg N1, 2.0 μg N2,
3.4 μg N3, 7.5 μg N4. The purity of the proteins was veriﬁed on non-re-
ducing SDS-PAGE stained with Coomassie Brilliant Blue (Fig. 2).
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identiﬁed the expected N-terminal sequence ↓ARLGARP… in all of the
NRTN variants (Fig. 1). In addition, a very small portion of WT and N2
was cleaved two amino acids after the expected cleavage site (AR↓-
LGARP…), similar to an additional cleavage site in GDNF (Piccinini et
al., 2013). These additional cleavage sites are important to take into ac-
count when designing assays with N-terminally tagged GFLs. Mass
spectrometry veriﬁed the molecular mass of the puriﬁed NRTN variants
to correspond to the expected theoretical mass of single protonated di-
mers without prominent posttranslational modiﬁcations (theoretical
mass/determined mass in Da, WT: 23,355/23,345, N1: 22,844/22,807,
N2: 22,844/22,822, N3: 22,504/22,469, N4: 22,165/22,143). Based on
these assays we considered the quality of the proteins suitable for func-
tional testing.
3.5. Stability of the puriﬁed proteins
When the puriﬁed NRTN variants N2, N3, N4 andWTNRTNwere in-
cubated at 37 °C at low concentration they were fully stable for four
weeks (described in Supplemental material and Fig. S3). However, WT
NRTN, N3 and especially N1 showed a strong tendency to precipitate
during concentration, puriﬁcation and biochemical assays. Therefore
we focused on N2 and N4 which give better yields, are more stable
and easier to handle.
3.6. Decreased afﬁnity of the puriﬁed NRTN variants to heparin
The heparin binding capacity of the puriﬁed untaggedNRTN variants
was determined by heparin afﬁnity chromatography. Commercial WT
NRTN eluted with a peak at 1.07MNaCl, WTNRTN from CHO cells elut-
ed at 1.08MNaCl and theNRTN variants at signiﬁcantly lower NaCl con-
centrations: 0.97 M (N1), 0.56 M (N2), 0.56 M (N3) and 0.48 M (N4)
(Fig. 3). These results are in full accordance with the initial screening
of the V5-tagged unpuriﬁed NRTN variants (Fig. S1). An example of
the technical difﬁculties with N1 is shown in Fig. 3: although the
amount of loaded N1 equaled that of the other NRTN variants, the pro-
tein was hardly detectable after elution. ARTN, NRTN and GDNF elute
with peaks of around 1.3 M, 1.1 M and 0.9 M NaCl respectively (Alfano
et al., 2007), while PSPN elutes with 0.5 M NaCl (Bespalov et al.,Fig. 3. Heparin afﬁnity chromatography analysis of puriﬁed, untagged NRTN variants. The pu
sequencing and mass spectrometric analyses. Thereafter the proteins were loaded on hep
gradient (right axis). The elution of the proteins was monitored by their absorption at 214 nm
the peak is indicated with an arrow (↑).2011). Therefore N2 and N4 are new GFL variants with exceptionally
low afﬁnities for heparin.
3.7. Biological activity of the puriﬁed NRTN variants in vitro
Due toNRTN aggregation and adhesion,we used afﬁnity chromatog-
raphy and 125I-NRTN binding to cells instead of Biacore assays for li-
gand-receptor afﬁnity studies. In line with results on WT NRTN (Cik et
al., 2000), all NRTN variants bind more strongly to GFRα2 than to
GFRα1. Furthermore, under stringent afﬁnity chromatography condi-
tions, in the absence of RET, the binding of the new NRTN variants to
both GFRα1 and GFRα2 receptors is slightly weaker than that of WT
NRTN (Fig. S4). The heel region is not directly involved in interactions
with the GFRα receptor in either ARTN or GDNF (Parkash et al., 2008).
Therefore this region was predicted to be optimal for makingmutations
which affect the binding of NRTN to heparin but not to GFRα2. The mu-
tations in the helix regionmight have a slight effect on the orientation of
the receptor-binding ﬁnger-like structures in NRTN (Fig. 1).
The presence of RET is known to stabilize the binding of GDNF to the
receptor complex (Virtanen et al., 2005). In binding assays on CHO cells
expressing GFRα2, RET and heparan sulfates, the mean IC50 value was
5.9 nM for WT NRTN from mammalian cells (n = 5), when measured
from cell lysates after competition with commercially available WT
NRTN from E. coli. When using intact cells, 125I-NRTN variants from
mammalian cells and homologous competition, the mean IC50 values
were 4.65 nM for WT NRTN (n = 2), 3.13 nM for N2 (n = 3) and
1.42 nM for N4 (n = 4) (Fig. 4A), showing that in the presence of RET,
WT NRTN, N2 and N4 have a similar afﬁnity to the GFRα2/RET receptor
complex.
To study whether the NRTN variants have the same capacity to acti-
vate RET as WT NRTN, we performed dose-dependent RET-phosphory-
lation assays. Based on two/three repetitions of the assays we conclude
that when the puriﬁed proteins are applied in cell culturemedia onto ﬁ-
broblasts transfected with either GFRα2 or GFRα1, all NRTN variants
can activate RET in a similar dose-dependent manner (Fig. 4B).
Next we compared the biological activity of WT NRTN and the
variants N2 and N4, in an in vitro survival assay on dopaminergic
neurons from dissociated mouse midbrains (E13.5), which express
GFRα1 (but not GFRα2) and RET (Cacalano et al., 1998), andrity of the proteins was veriﬁed by SDS-PAGE, and further characterized by N-terminal
arin afﬁnity chromatography column from which they were eluted with a linear NaCl
(left axis). The salt concentration at the elution peaks is shown for each protein. For N1
Fig. 4. Receptor activating capacity of the puriﬁed untaggedNRTNvariants. (A) Examples of cell-based binding assay on CHO cells transfectedwith GFRα2 and RET. IodinatedWTNRTN, N2
or N4 was added to the cells in the presence of increasing concentrations of the corresponding unlabeled NRTN variant. The background (→) was in each case determined on CHO cells
transfected with GFP and RET. 125I was monitored as counts per minute (cpm) from cell lysates or counts per second cells (cps) from intact cells. The number of parallel data points
used to plot each graph is 4 for WT when measured from cell lysates and at least 7 for WT/N2/N4 when measured on intact cells. Error bars indicate SEM. For IC50 calculations each
experiment was repeated 2–5 independent times. (B) Dose-dependent RET-phosphorylation assays. The puriﬁed NRTN variants (N2-N4, WT), commercial NRTN from E. coli (WT*) or
GDNF (1–90 ng/ml) were used to stimulate MG87-RET cells transiently transfected with either GFRα1 or GFRα2. WT* was used for normalization at 3 and 10 ng/ml (3* and 10*). The
immunoprecipitates were analyzed after Western blotting, with antibodies to phosphotyrosine (P-Tyr, left) and RET (right). The cell surface-located form of RET (170 kDa) is indicated
with an arrowhead (►).
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assay N2, N4 and WT NRTN exhibited similar activity (one-way
ANOVA, Tukey's post hoc test for differences between treatment
and control) (Fig. 5A).
To compare the biological activity of the NRTN variants in tissue, we
used mouse embryonic kidney cultures. GDNF induces extra ureteric
budding and swelling of the deﬁnitive ureteric tips when added to kid-
ney cultures (Sainio et al., 1997). However, although NRTN induces ure-
teric branching in organ cultures, it appears unable to induce ectopic
buds (Davies et al., 1999). Accordingly, under our experimental condi-
tionsWTNRTN (from both E. coli andmammalian cells) failed to induce
ectopic ureteric budding even at 500 ng/ml. Interestingly, both N2 and
N4 induced ectopic ureteric buds and swelling of the deﬁnitive buds.
The stronger activity of N2 and N4 correlates with a higher stability of
these proteins in themedia of the kidney cultures (Fig. 5B), and possibly
with a better diffusion in the tissue. It should be noted that N2 and N4
also showed an improved stability in the cell culture media of mamma-
lian cell lines (Fig. S2).
The afﬁnity of the NRTN variants to GFRα2 enabled a puriﬁcation
method based on GFRα2-afﬁnity chromatography. The biological activ-
ity of the puriﬁed NRTN variants was furthermore veriﬁedwith binding
assays, dose dependent RET-phosphorylation assays, in vitro survival as-
says and kidney in vitro organogenesis assays. We conclude that themutations in the heel region affect the structure of NRTN only slightly,
without impairing its biological activity.
3.8. Attachment to the cell surface and diffusion of the NRTN variants in the
rat brain
GDNF, NRTN andARTNattach to cells either by binding to GFRα or to
heparan sulfated proteoglycans (Bespalov et al., 2011). Here we show
that while WT NRTN attaches to the cell surface of CHO cells lacking
GFRα receptors, N4 does not. When the cells are transfected with plas-
mids encoding GFRα2 receptors, both ligands attach to the cell surface
(Fig. 6A). When CHO pgsA 745 cells, lacking heparan sulfates (deﬁcient
in xylosyltransferase and unable to initiate glycosaminoglycan synthe-
sis), were used in the same type of experiments, neither ligand attached
to the cell surface in the absence of GFRα2 (Fig. 6B).
In vivo the afﬁnity of GFLs to extracellular heparan sulfates depends
on the precisely regulated biochemical modiﬁcation of these carbohy-
drates (Bespalov et al., 2011; Rickard et al., 2003). Immunohistochemi-
cal staining of rat brains 24 h after injection of the proteins (5 μg), shows
that N2 (126mm3) and N4 (217mm3) diffused better than commercial
WT NRTN (57 mm3) (Fig. 6C–D). Although binding of NRTN to heparan
sulfates couldmediate protection fromproteolysis and extracellular sta-
bility (Rickard et al., 2003), N2 and N4 show an improved resistance to
Fig. 5. In vitro activity assays using puriﬁed untagged NRTN variants (A) In vitro survival assay on embryonic dopaminergic neurons. Tyrosine hydroxylase positive cells were counted after
survival induction with NRTN variants (N2, N4,WT) and commercial NRTN from E. coli (WT*) at 0.3–10 ng/ml. The number of tyrosine hydroxylase positive cells in the absence of ligands
(buffer)was used as a control (100% survival). The results are shown after subtraction of this baseline (100%) control. Each experimentwas doneusing two replicatemicro islands andwas
repeated 3–8 independent times. Error bars indicate SEM., p b 0.05 (*), p b 0.01 (**), p b 0.001 (***). (B) Embryonic kidney organogenesis assay. Kidney explants were incubated with
puriﬁed N2, N4 or WT NRTN (500 ng/ml) for 48 h and stained with anti-calbindin antibodies. Scale bar 200 μm. Explants incubated without added ligands were used as a control
(Contr.). Under each kidney explant is a Western blot analysis of the amount of NRTN in the media at 0, 2, 6 or 24 h. Please note that the antibody to NRTN recognizes dimeric WT
NRTN about ﬁvefold more efﬁciently than N2 and N4 (see Fig. 6E). The arrowhead (►) indicates 20 kDa.
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histochemical staining 24 h after injection into rat brains (Fig. 6C). The
weaker staining of N4 could be due to the dilution factor and the afﬁnity
of the anti-NRTN antibody: inWestern blots the afﬁnity of this antibody
is signiﬁcantly lower for N2 and N4 than for WT NRTN (Fig. 6E).
3.9. Biological activity of N2 and N4 in a rat 6-OHDA model of PD
The neurorestorative activity of the NRTN variants in vivowas tested
in a rat 6-OHDAmodel of PD (Kirik et al., 2000). Traditionally high doses
of GFLs are used in rat models of PD (up to 100 μg). To distinguish be-
tween the effects of the different proteins, we used a severe lesion
(28 μg 6-OHDA intrastriatally) and a relatively low dose of the proteins
(5 μg, injected intrastriatally two weeks after the lesion) (Fig. 7A). In
these experiments the injection volume is a limiting factor (10 μl).
Since WT NRTN precipitated at concentrations above 0.1 μg/μl we
were unable to include it in this set-up. N2 and N4 were compared to
the vehicle and to commercial GDNF from E. coli (used in clinical trials,
and considered as gold standard in animal models).
As a behavioral read-out of the unilateral dopamine deﬁcits we used
amphetamine-induced rotation assays and a non-pharmacological cyl-
inder tests. Analysis (repeated measures ANOVA) of the results from
the rotation assays revealed signiﬁcant drug treatment effects
(F3,40=3.2, p=0.033). The Fisher PLSD post hoc test showed signiﬁcant
differences between the vehicle- and N4-treated rats (p b 0.01), be-
tween N2- and N4-treated rats (p b 0.05) and between GDNF- and
N4-treated rats (p b 0.05) (Fig. 7B). Statistical analysis (Kruskal-Wallis
non-parametric ANOVA) of the results from the cylinder test also re-
vealed a signiﬁcant drug treatment effect after ten weeks (p =0.0138). The Dunn's Multiple comparison test showed a signiﬁcant dif-
ference between the vehicle- andN4-treated groups (p b 0.05) (Fig. 7C),
but not for GDNF.
TH-positive cells in the substantia nigra and TH-positive ﬁbers in the
striatum were quantiﬁed after the rotation assay at twelve weeks. Sta-
tistical analysis (one-way ANOVA) of the number of TH-positive cells
in substantia nigra revealed signiﬁcant drug treatment effects
(F3,40 = 2.951, p = 0.0441). Post hoc analysis with Fisher's PLSD test
showed a signiﬁcant difference between all treated groups and the ve-
hicle group (p b 0.05) (Fig. 7D). Statistical analysis of TH-positive
neurites in the striatum, (one-way ANOVA), also revealed signiﬁcant
drug treatment effects (F3,40 = 4.24, p = 0.011). The Fisher PLSD post
hoc test showed signiﬁcant differences between vehicle- and N4-treat-
ed rats (p b 0.01), N2- and N4-treated rats (p b 0.01), as well as
GDNF- and N4-treated rats (p b 0.05) (Fig. 7E), but not between vehicle
and GDNF.
Our results with read-outs from four independent methods (cylin-
der test, amphetamine induced rotation, number of TH-positive cell
somas in substantia nigra and ﬁber density in the striatum), at different
time points are coherent, and show that mammalian N4 improves the
conditions of the 6-OHDA lesioned animals, better than GDNF from E.
coli. It should be noted that N4 improved the conditions of the rats in
spite of its small dose (5 μg) in severely lesioned rats (28 μg 6-OHDA).
3.10. Diffusion of N2 and N4 in non-human primate brains
Equimolar amounts of GDNF (225 μg/225 μl), N2 (170 μg/170 μl) and
N4 (170 μg/205 μl) were infused into the putamen of cynomolgus
monkey brains (n = 1). Immunohistochemical staining shows that
Fig. 6.Attachment to the cell surface and diffusion of theNRTN variants in rat brains. (A) Binding of NRTN variants to CHO cells. Untransfected cells (left) andGFRα2-transfected cells (α2)
(right)were incubatedwith untaggedWTNRTN (WT), V5-taggedWTNRTN (V5-WT) or V5-taggedN4 (V5-N4) and stainedwith antibodies to V5. Scale bar 30 μm. (B) Binding of NRTN to
CHO cells with an intact or defective synthesis of glycosaminoglycans. Untransfected CHO (CHO) or pgsA-745 (pgsA) cells were incubated with V5-tagged WT NRTN and stained with
antibodies to V5 (left) and Hoechst to visualize the nuclei (right). Scale bar 30 μm. (C) Diffusion of the NRTN variants in the rat brain. The untagged NRTN variants N2 and N4 as well
as commercial NRTN from E. coli (WT*) (5 μg) were unilaterally injected into the striatum and detected by IHC. The panels in the middle represent sections at the injection site (AP
+1.0). Sections 1 mm apart from the injection site are shown to the left (AP +2.0) and right (AP +0.0). Scale bar 7 mm. (D) Overview of the total diffusion volumes of WT*, N2 and
N4 in all analyzed rats. (E) Characterization of the afﬁnity of the antibodies to NRTN. WT NRTN (5, 10 ng), N2 (25, 50 ng) and N4 (25, 50 ng) were analyzed by Western blotting with
antibodies to NRTN (upper panel) or stained with Coomassie brilliant blue (lower panel), the arrowhead (►) indicates 20 kDa.
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same volume although N2 was applied in a 25% smaller infusion
volume. N4 (1228mm3) diffused over the biggest volume (Fig. S5). Im-
munohistochemical staining of marmoset monkey brains (n = 3) 8 h
after injection of the proteins (5 μg), shows that N4 (106.1 mm3) dif-
fuses signiﬁcantly better (p = 0.018) than commercial GDNF
(18.4mm3) (Fig. 8A, S6). Taken together our results show that especial-
ly N4 has a decreased afﬁnity to heparin (Figs. S1C, 3), and to heparan
sulfated proteoglycans on the cell surface/extracellular matrix in vitro
(Fig. 6A–B). NRTN variant N4 also displays an improved diffusion in
rat and monkey brain tissues in vivo (Fig. 6C–D, 8A–B, S5, S6).3.11. Expression of N2 and N4 receptors in human basal ganglia
It is worth to note that both N2 and N4 are active in mouse embry-
onic dissociated midbrain cultures, as well as in mouse kidney organo-
genesis assays, although GFRα2 is lacking from these tissues (Cacalano
et al., 1998; Golden et al., 1999).These assays show that the biological
activity of N2 and N4 can be mediated not only by GFRα2/RET but also
GFRα1/RET. Successful clinical use of NRTN depends on the expression
of the signal transducing receptors in the target tissues. The expression
of GFRα1 and RET has previously been detected by quantitative real-
time RT-PCR in the putamen of elderly humans, with no signiﬁcant
Fig. 7. In vivo assays in a rat 6-OHDA lesion model. (A) Schema of the assay. After the 6-OHDA lesion (2 weeks), 5 μg of commercial GDNF, N2 or N4 were injected unilaterally into the
striatum. The rats (vehicle: n = 9, GDNF: n = 10, N2: n = 12, N4: n = 13) were characterized by (B) amphetamine-induced rotation assays at weeks 8 and 12, (C) cylinder tests at
week 10, (D) IHC estimation of TH-positive cell somas in SNpc at 12 weeks, (E) IHC quantiﬁcation of TH-positive ﬁber density in the striatum at 12 weeks, signiﬁcant difference to
vehicle, p b 0.05 (*), p b 0.01 (**).
Fig. 8. Diffusion of the NRTN variants in rat and monkey brains and expression analysis of the receptors in human brains (A) Volume measurements show a signiﬁcantly (p= 0.018)
improved diffusion of N4 compared to GDNF in marmoset monkey brains (n = 3), see Fig. S6 for an overview of all sections used for the volume estimations. (B) Comparison of the
spreading of N4 compared to N2, WT NRTN or GDNF in rat brains, n = 3, diffusion time 24 h (see Fig. 6C-D), cynomolgus monkey brains, n = 1, diffusion time 2 h (see Fig. S5) and
marmoset monkey brains, n = 3, diffusion time 8 h (see Fig. S6). A summary of the experimental parameters is given to the left. (C) RT-PCR analysis of mRNA encoding GFRα1,
GFRα2 and RET in human basal ganglia. GAPDH was included for normalization. RNAs were from substantia nigra (SN), globus pallidus (GP), putamen (P) and whole brain (B).
Samples incubated without reverse transcriptase are marked with a minus, W 1 and W 2 are water controls described in the materials and methods. The ladder (L) used for GFRα1/2
and RET is from the bottom 100, 200, 300, 400, 500, 600 bp and for GAPDH 50, 100, 150, 200, 250, 300 bp.
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whether GFRα2 is expressed in humanmidbrain we performed RT-PCR
analysis of adult human tissues. Our results show thatmRNAs of GFRα2,
GFRα1 and RET are expressed in human substantia nigra, globus
pallidus and putamen (Fig. 8C).4. Discussion
GDNF and NRTN have given modest and controversial results in PD
clinical trials (Lang et al., 2006; Marks et al., 2010; Bartus and Johnson,
2016a; Bartus and Johnson, 2016b; Bartus et al., 2011, Ceregene, Press
release 21.5.2013). Controversy surrounds the intraparenchymal infu-
sions of GDNF protein (produced in E. coli) with the ﬁrst studies
reporting signiﬁcant improvement in motor function but the blinded
phase II trials failing to do so. Non-human primate studies have
shown marked variability of GDNF distribution when infused in the
same way as in the phase II study, and motor improvement was only
seen in animals with the widest GDNF distribution. Gene therapy-
based clinical trials with NRTN have not achieved their primary end-
point of motor improvement. Autopsy showed only modest changes
in TH-positive cell numbers and very limited NRTN distribution around
the injection sites. Consideration of the poor and variable distribution
led us to create better diffusing NRTN variants with a decreased afﬁnity
to heparan sulfates in the extracellular matrix and on the cell surface.
We validated the improved spreading of these variants in brain tissue
of rats, cynomolgus and marmoset monkeys.
The molecular properties of NRTN are important to take into ac-
count in PD clinical trials. It is well established that low concentra-
tions of GFLs (10 ng/ml) trigger RET activation in vitro. According
to these results, 80 ng would be enough so to cover the two-sided
human putamen, which has a volume of b8 ml (Yin et al., 2009). In-
stead intriguingly high doses of 3–43 μg/day (Gill et al., 2003; Slevin
et al., 2005; Lang et al., 2006) have been used in clinical trials. It could
be that some protein chemical properties of GFLs have necessitated
the use of excessive in vivo doses. NRTN is very prone to precipitate
at increased protein concentration (above 0.1 μg/μl) and upon buffer
exchange. Therefore the transition of high amounts of NRTN from the
injection buffer to the tissue implies high precipitation risks for this
protein. Inside the tissue the diffusion of NRTN is severely hampered
by its high afﬁnity to heparan sulfates. Here we modiﬁed NRTN with
the intention to decrease its afﬁnity to heparan sulfates. This modiﬁ-
cation turned out to improve also the stability of the protein and fa-
cilitate its handling. To optimize protein folding and dimerization,
both important for receptor activation, we used a mammalian ex-
pression system for production of the mutants. Taken together, im-
proved chemical properties of NRTN are highly relevant for
therapeutic efﬁcacy and success in clinical trials.5. Conclusions
For treating patients with Parkinson's disease, we designed and
characterized NRTN variants with an increased diffusion. The improved
diffusion of these novel NRTN variants is particularly relevant in
humans, with brains about six hundred times bigger than those in
rats. In our rat 6-OHDA model of PD the NRTN variant N4 shows a
clear improvement in motor function and protects and repairs dopa-
mine neurons in vivomore efﬁciently than GDNF from E. coli. This may
not be due only to an improved diffusion, but also to an increased pro-
teolytic stability. For these reasons the NRTN variants N2 and N4 are
good candidates for the treatment of PD and are currently being tested
in non-human primate models of PD. Whether our newly created neu-
rotrophic factor variants with improved diffusion and stability will slow
or reverse the degenerative process of PD will have to await human
trials.Conﬂict of interest
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